• Wearable wellness technology innovator MetAlert is revitalizing its brand and increasing its product and services portfolio through M&A and other corporate developments designed to improve the company’s healthcare profile
• The mortality associated with chronic disease can be ameliorated with the use of wearable devices, along with other healthful practices, and the use of wearable wellness technology is expected to continue at an increasing pace
• More than 41 million people die of noncommunicable diseases (aka chronic illnesses) each year — 17 million of them before the age of 70, according to the World Health Organization
• MetAlert’s growing product slate is designed to combine unobtrusive wearability, tracking technology, telehealth communication capabilities, and artificial intelligence, to serve the needs of patients and caregivers

For many people, the beginning of a new year signals a time to renew efforts at self-betterment through increased exercise and other healthful practices. One means of measuring improvements that has become popular in recent years is the use of a pedometer to track the wnumber of the wearer’s “steps” in a given day, and smartwatches have made such wearable devices unobtrusive and easily accessible (https://ibn.fm/rs2hb).

The modern variety in wearable technologies has gained increasing use in part because the devices may enable individuals to self-assess their goals and conditioning without the need to visit to visit medical clinics to obtain physiological data and analyze it for biomedicine, healthcare and wellness purposes.

Big data analyst PatSnap reports more than 722 million wearable devices were in use worldwide in 2019 and that they are expected to reach one billion by the end of this year, calling wearable devices “the new healthcare revolution”, and anticipating that the wearable technology industry will see a CAGR of 13.67 percent between this year and 2027 (https://ibn.fm/z9Zwa).

Location-sensitive health monitoring wearable device developer MetAlert (OTC: MLRT) is building its product portfolio and profile of affiliated companies, working to become a market leader in the wearable technology industry.

The company’s patented GPS SmartSole shoe insoles have become its flagship offering in delivering a solution for those at risk of wandering or becoming lost or disoriented due to Alzheimer’s disease and other dementias, autism, or traumatic brain injury, and MetAlert is expanding its sights with products that may help protect fall-prone patients and grant them confidence-building independence, as well as small tracking devices with increased battery life and products that provide telehealth connectivity and assessment tools.

According to the World Health Organization (“WHO”), noncommunicable diseases (NCDs, also known as chronic illnesses) claim the lives of some 41 million people each year — 17 million annually before they reach the age of 70. The agency notes physical fitness, good eating habits, safe alcohol use and tobacco avoidance are all important in improving a patient’s potential to avoid dying from an NCD (https://ibn.fm/N50kM).

An increase in attention to lifestyle wellness factors is expected to continue raising the overall age of the world’s elderly population, but with increasing age the prevalence of chronic diseases such as dementia, heart disease, and diabetes increases as well, indicating the market potential for wearable devices that may help patients cope with their conditions as successfully as possible.

“Strategic acquisitions, expanding our products and services, and increasing our revenues per user (‘RPU’), should help set us on a path toward continued success in the coming months and years”, MetAlert CEO and Founder Patrick Bertagna stated in a Jan. 5 letter to the company’s shareholders (https://ibn.fm/tAkQF). “Moreover, aligning with new technologies could open possibilities for crucial data analysis that has the potential to revolutionize how we conduct and manage healthcare worldwide.”

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers
• The study shows promising prophylactic results with hamsters receiving BiondVax’s inhaled NanoAb three hours before infection experiencing no significant weight loss over the six-day trial; follows previously reported data showing successful use of NanoAb as COVID-19 therapeutic
• First-in-human Phase 1/2a clinical trial is planned for later this year

Focused on the development, manufacture, and commercialization of innovative NanoAb immunotherapeutic products, BiondVax Pharmaceuticals (NASDAQ: BVXV) recently announced additional results in the company’s preclinical proof-of-concept study of its inhaled nanosized VHH-antibody (NanoAb) COVID-19 drug (https://ibn.fm/Kz8W4). BiondVax is developing a pipeline of innovative alpaca-derived NanoAb drugs addressing diseases with large underserved medical needs and attractive commercial opportunities, such as COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. The research is being done as part of a collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen.

The study was designed to mimic a real-world situation in which at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare professionals may proactively protect themselves prior to potential SARS-CoV-2 exposure using BiondVax’s self-administered inhaled NanoAb therapy.

Using an industry-standard animal model, the study compared weight loss in two groups of hamsters. The hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial. In contrast, the hamsters in the untreated control group experienced a 12% decline in weight, a highly statistically significant difference (p<0.0005).

The promising prophylactic results follow previously reported data from the same study indicating that compared to the control (placebo) group, hamsters treated with a 2mg dose of BiondVax’s inhaled NanoAb one day after infection had negligible (below detection level) SARS-CoV-2 viral titers in their lungs, and experienced a milder and shorter illness compared to the placebo group that had at least 30-times higher viral titers in their lungs at the end of the trial. Additionally, lung histopathology revealed that therapeutic inhalation of NanoAbs reduced damage to alveoli, pulmonary vessels, and the conductive system.

“We continue to be thrilled with the results of this ongoing trial. There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion. EVUSHELD is currently the only prophylactic COVID medication with FDA approval under emergency use authorization,” BiondVax CEO Amir Reichman said. “Our inhaled NanoAb is designed to be self-administered at the time of choosing to generate rapid protection from COVID illness. In contrast, EVUSHELD must be administered via two separate consecutive intramuscular (‘IM’) injections in a health care setting… we believe the additional ‘biobetter’ value provided by our NanoAb potentially positions it to capture significant market share both for treatment and prevention of COVID illness.”

The preclinical trial’s next step is to continue with additional arms testing lower therapeutic doses. It will also evaluate safety parameters. The results of the dosing study will inform the design of future studies of BiondVax’s inhaled NanoAb expected in 2023, including a preclinical toxicity study to assess safety as required by regulatory authorities for approval of human clinical trials. BiondVax is also expected to scale up its manufacturing processes to produce, at its Jerusalem GMP manufacturing facility, the NanoAbs for the first-in-human Phase 1/2a clinical trial planned for Q4 2023.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Small to mid-cap-sized public companies often struggle to include salaries for full-time chief information security officers (“CISOs”) in their budgets, and to establish protocols for their resiliency in the wake of cybercrime incidents
• Cybersecurity services and technology provider SideChannel Inc. provides virtual chief information security officer (“vCISO”) services as a per-contract consultancy to SMBs, helping them to manage finances and security at the same time
• The U.S. Securities and Exchange Commission (“SEC”) is expected to finalize rules this year that would provide investors with a transparent view of public company boards’ C-suite-level cybersecurity profiles
• SideChannel CEO Brian Haugli has made appearances in numerous media forums as a go-to cybersecurity expert and he will participate Feb. 15 in an Investor Day event structured in a virtual webcast format (information and registration at https://ibn.fm/qRYcq)

The U.S. Securities and Exchange Commission’s pending rules change, designed to promote transparency on public company boards regarding the level of cybersecurity expertise present among their C-suite members, is serving as a wakeup call to corporate leaders who perhaps have been complacent about their vulnerability to cyber attack.

A November Harvard Business Review report noted that recent research in company boardrooms found that most board members consider cybersecurity important, and that cybersecurity is regularly discussed in each board meeting, but it also found that 47 percent of respondents believe their organization is unprepared for a cyber attack and that about a third of board members say they only interact with the chief information security officer during scheduled presentations to the board (https://ibn.fm/W6H1c).

In response to expectations that the Securities and Exchange Commission will soon require companies to disclose their cybersecurity governance capabilities, including whether the entire board, a specific board member, or a board committee is responsible for the oversight of cyber risks, C-suite recruiting firm DHR Global conducted its own research, which found that only 1.4 percent (seven out of America’s top 500 public companies) said they have a current or former CISO on their board.

DHR further reported that only 23 percent of the companies said they have a current or former chief information officer on their boards, and that most companies — 65 percent — simply assigned cybersecurity responsibility to their audit committees (https://ibn.fm/Ctc8C).

While many small and mid-cap public companies may struggle with having to dedicate budgets to cybersecurity resiliency and employing a full-time CISO, cybersecurity services and technology provider SideChannel (OTCQB: SDCH) is providing an alternative solution with its team of experienced virtual CISOs — experts available to consult with clients on contract without the need for a staffing commitment.

The vCISO contracts generally last 12 months with options for annual renewal and a monthly subscription plan. SideChannel’s annual report to the SEC noted that each of its vCISOs is generally embedded into the C-suite executive teams of its clients, providing them with “the C-suite cybersecurity leadership needed to effectively mitigate cybersecurity risks and support ongoing operation of critical business functions” (https://ibn.fm/K2PQu).

CEO Brian Haugli has been increasing SideChannel’s visibility as the public face of the company, enjoying placements with top-tier US and Canada media (CBC, NBC News, FOX Business) as a go-to cybersecurity expert and inclusion in numerous reports online and with other national media outlets, including Fast Company Sinclair Broadcast Group.

Services such as SideChannel’s vCISOs and its proprietary microsegmentation software platform (Enclave) for sustaining encryption against cybercrime can help public companies best prepare for the SEC’s transparency rules.

“Cybersecurity incidents and other risks are considered one of the largest threats to companies. Accordingly, investors may find disclosure of whether any board members have cybersecurity expertise to be important as they consider their investment in the registrant as well as their votes on the election of directors of the registrant,” the SEC stated in announcing its intention for new rules last March (https://ibn.fm/ZYwaE).

The commission is expected to finalize the rules early this year.

“We believe most public companies of all sizes are ill-prepared for upcoming SEC regulations on cybersecurity and risk assessment,” DHR partner in the Board & CEO Practice Heather Smith stated in her company’s report. “It’s obvious that a sea change is underway at the board level. As a result of the SEC identifying the need and issuing new guidance, we’ve already had a number of boards looking to hire CISO board directors who understand the latest vulnerabilities and best strategies on cyber risk.”

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• AZMCF expanding the 100%-owned Kay Mine Projects in Arizona, surrounded by sixty historic underground VMS copper, gold, zinc, and silver mines
• Volcanogenic massive sulfide (“VMS”) deposits are critical global sources of copper, zinc, lead, gold, and silver ores
• Recent company update reveals progress on Kay Mine Project, including 33,000 meters of core drilling completed in 2022, drill permits received for Central and Western targets, and drilling initiated on targets outside deposit
• Company fully funded (cash of $58 million at Sept 30, 2022) to complete remaining 8,600 meters for Kay Mine Phase 2, as well as 76,000 meters for Phase 3

Arizona Metals (TSX: AMC) (OTCQX: AZMCF), a mineral exploration company, recently provided a year-end review and updates on its 100%-owned Kay Mine VMS Project and Sugarloaf Peak Gold Project in Arizona (https://ibn.fm/Uvy2n). During 2022, the company completed approximately 33,000 meters of core drilling at the Kay Mine Deposit, received drill permits for both the Central and Western Targets, and initiated drilling on targets outside the deposit.

As of September 2022, AZMCF was fully funded to complete the remaining 8,600 meters planned for the Kay Mine Phase 2 program, and an additional 76,000 meters for Phase 3. Both programs will test numerous parallel targets west of the Kay Mine Deposit, along with possible northern and southern extensions.

“As we begin 2023, I want to take a moment to reflect on the past year and share some of our accomplishments,” said AZMCF CEO Marc Pais. “First, I want to thank our shareholders for your continued support and belief in Arizona Metals. Your trust and investment have been a driving force in creating one of the best-financed explorers listed on the TSX and advancing what we believe to be one of the world’s premier VMS exploration projects.”

Volcanogenic massive sulfide (“VMS”) deposits represent a critical global source of copper, zinc, lead, gold, and silver ores. AZMCF aims to tap into the potential of Arizona’s Yavapai County with its 100%-owned projects surrounded by sixty historic underground VMS copper, gold, zinc, and silver mines.

VMS ore deposits are typically associated with and created by volcanic-associated hydrothermal events in submarine environments (https://ibn.fm/uvwM4). They are predominantly copper-zinc metal sulfide ore deposits occurring in areas dominated by volcanic or volcanic-derived rocks. Currently, VMS deposits are formed around volcanoes under the sea and along many ridges in the middle of the ocean within forearc rifts and back-arc basins. While some mineral exploration firms explore on the sea floor, most companies focus on land-based equivalents.

Yavapai County, located in mining-friendly Arizona, is a prolific mining district with substantial historic resources, one of which AZMCF is currently exploring, developing, and expanding. The company’s fully owned flagship Kay Mine property totals 1,300 acres that are not subject to any royalties. A historic 1982 estimate by Exxon Minerals revealed a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver” (https://ibn.fm/C2zjb). (1)

According to a report by Westworld Resources in 1983, AZMCF’s fully owned Sugarloaf Peak Property in La Paz County has a historical estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. (2)

Based in Toronto, Canada, Arizona Metals advances precious and base metal deposits in Arizona. The company’s management team leverages decades of geological engineering, precious metals exploration, and investment banking experience to develop world-class VMS exploration projects.

(1) The historic estimate at the Kay Mine Deposit was reported by Exxon Minerals in 1982. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

(2) The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

For more information, visit the company’s website at www.ArizonaMetalsCorp.com.

Full Disclosure: Arizona Metals Corp. is an InvestorBrandNetwork marketing client.

NOTE TO INVESTORS: The latest news and updates relating to AZMCF are available in the company’s newsroom at https://ibn.fm/AZMCF

• Every country in the world signed the Paris agreement at COP 21 in 2015, 50+ countries have committed to Net-Zero by 2050
• GeoSolar helps ease energy transition with the SmartGreen(TM) whole-home renewable energy system
• GeoSolar’s SmartGreen(TM) system offers a total-home makeover, including geothermal-powered heat pump, solar panels, upgrades to insulation, windows, lighting systems

Every country in the world signed the Paris agreement at COP 21 in 2015 with the shared aim of limiting global temperature increases as close as possible to 1.5 degrees Celsius (https://ibn.fm/iDbjH). Since then, over 50 countries have committed to adopting a net-zero emissions goal by 2050 – including the United States (https://ibn.fm/kqTZ5). GeoSolar Technologies (“GST”), a Colorado-based climate technology company, helps ease the transition with the SmartGreen(TM) Home system for newly built and existing residences and commercial buildings.

Individual states throughout the US are also taking measures to promote renewable energy and reduce carbon emissions. GeoSolar’s home state of Colorado is among those taking bold steps to achieve Net-Zero through a proposed bill that uses 2005 benchmark levels to set greenhouse gas reduction goals of 65% by 2035, 80% by 2040, 90% by 2045, and 100% in 2050 (https://ibn.fm/skbhP). Other states are also taking action to reduce emissions, including Washington State, California, Illinois, New York, and New Jersey (https://ibn.fm/ONa4j).

GeoSolar’s SmartGreen(TM) whole home energy system helps building owners achieve energy independence while eliminating carbon emissions. Geothermal ground loops, air ducts, and photovoltaic solar panels tap into the energy of the earth and sun to power electric appliances and vehicles. In addition, the SmartGreen(TM) system improves efficiency throughout the entire home by tightening the building envelope and upgrading insulation, windows, and lighting systems.

SmartGreen(TM) is suitable for warm and cold climates and can be retrofitted to existing buildings or integrated into new construction. Besides offering energy independence, the SmartGreen(TM) system can also drastically reduce or eliminate utility bills and increase the building’s value.

GeoSolar aims to market SmartGreen(TM) to over 120 million homes across the United States with 100% financing options, valuable tax deductions, and utility incentives. The company is also giving the public an opportunity to own a piece of GeoSolar Technologies Inc. and the SmartGreen system through a Reg A+ capital raise that enables anyone to become a shareholder.

For more information on GeoSolar’s Regulation A+ capital raise, please visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders
• The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far
• 1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program and commence Phase 1(b) clinical study evaluating the safety and tolerability of DehydraTECH(TM)-processed CBD as a treatment for hypertension
• The company will also be pursuing commercial relationships in 2023 even as its R&D continues to progress by engaging in discussions with potential collaborators who may license the patented DehydraTECH technology

Lexaria Bioscience (NASDAQ: LEXX) started calendar 2022 with optimism, which according to CEO Chris Bunka’s recently published annual letter to shareholders (https://ibn.fm/zu8hP), turned out to well founded. Now, as the company begins calendar 2023, “that optimism is, if anything, even stronger today.” Lexaria has reason to be optimistic about the current year, coming off a year that saw it successfully fulfill its primary objectives and tick most, if not all, of the boxes on its priority list.

At the start of calendar 2022, the company intended to introduce its patented DehydraTECH(TM) drug delivery technology to world-leading collaborators and to avoid raising additional funds through the capital markets. It also planned to develop its DehydraTECH-CBD hypertension program, explore whether DehydraTECH-nicotine pouches could replace nicotine administration via inhalation (smoking), and evaluate DehydraTECH-CBD as a therapeutic against other conditions such as epilepsy, dementia, and diabetes. Lexaria, through Chris Bunka’s letter, is pleased to report that these objectives were wholly completed in 2022 or are nearing completion in early 2023.

The completed objectives include the introduction of DehydraTECH to potential licensees via ongoing discussions as well as the completion of EPIL-A21-1 animal study evaluating DehydraTECH-CBD as an anti-seizure therapeutic and the HYPER-H21-4 human clinical study evaluating DehydraTECH-CBD as a potential treatment for hypertension.

The results affiliated with the primary objectives of the HYPER-H21-4 study, namely the blood pressure and pharmacokinetic performance, were positive, with no serious adverse events observed. It is, therefore, accurate to say that the study was a success, Bunka writes. Moreover, in the EPIL-A21-1 study, DehydraTECH-CBD demonstrated certain performance enhancements, namely more efficacy at lower doses and more rapid action, than Epidiolex, a leading CBD-based anti-seizure medication. Of note, and following the success of the EPIL-A21-1 seizure study, Bunka writes, Lexaria is rating its DehydraTECH-CBD for seizure investigation as one of its highest priorities along with the DehydraTECH-CBD for hypertension and DehydraTECH-nicotine.

In the Q1 of calendar 2023, the company expects to complete dosing in the human nicotine study NIC-H21-1, the animal diabetes study, and the animal dementia study, having initiated them in late 2022. The company is also evaluating a series of secondary objectives of HYPER-H21 4 study, with some of the findings and additional results expected within this period.

Remarkably, the company achieved these milestones and managed the growth while exercising excellent fiscal controls. In fact, and despite the inflationary pressures, Lexaria hit its annual 2022 budget, +/- about 2%, building on an accomplishment that began in 2021. This helped the company preserve its existing capital and stay true to its earlier commitment not to raise additional funds by issuing equity or taking on any debt. As a result, its cash in hand is enough to support operations through nearly all of 2023 without needing to raise additional capital if the company chooses to reduce its R&D spending.

“However, as we prefer to keep advancing our applied R&D at as rapid a pace as we can, we are also continuing to pursue capital-strengthening possibilities that do not involve the issuance of any equity,” Bunka writes.

According to the letter, the R&D programs and the capital-strengthening opportunities are interlinked. If successful, the DehydraTECH-CBD hypertension program, for example, is expected to help increase not only Lexaria’s corporate value but also the probability of reaching one or more commercial out-licensing agreements within the pharmaceutical industry. In addition, the success could also pave the way for more commercial pursuits of its DehydraTECH-CBD for therapeutic use. Similarly, if the nicotine study is successful, the company feels it will have inched closer to completing its scientific investigations, positioning it to market the technology to the global nicotine industry in pursuit of growing revenue streams.

“Each of these three areas of investigation [DehydraTECH-CBD as a hypertension therapeutics, DehydraTECH-CBD as an anti-seizure medication, and DehydraTECH-nicotine] has the potential to support important industry relationships that prove meaningful or even transformative for Lexaria. Because of the obvious medical and market needs in each of these three sectors, we will be pursuing commercial relationships in 2023 even as our R&D continues to progress,” the letter reads.

Accordingly, Lexaria’s CEO expects calendar 2023 will be the company’s “best year ever.” Among the key milestones the company intends to achieve is a Food and Drug Administration (“FDA”) registration for an Investigational New Drug (“IND”) program that will sanction the commencement of a Phase 1(b) FDA-registered clinical trial evaluating the safety and tolerability of DehydraTECH-CBD as a treatment for hypertension. The company expects this research program will dominate the second half of calendar 2023 and beyond.

In all, the registered clinical trials for DehydraTECH-CBD are expected to culminate in the filing of a new drug application (“NDA”) via the abbreviated 505(b)(2) pathway. To support this shortened route to commercial approval, Bunka says, Lexaria will leverage precedent safety data generated from the clinical study of FDA-approved Epidiolex. In its trials, for example, Epidiolex demonstrated the pharmaceutical’s safety and tolerability when administered chronically but at much higher doses than Lexaria’s intended dosing of DehydraTECH-CBD.

Still, the company maintains that DehydraTECH-CBD is not its only long-term plan for FDA registration. “Stakeholders can follow our progress in other areas of therapeutic interest through the results we receive in our applied R&D programs,” emphasizes Bunka.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Backcountry aviation innovator CubCrafters is advancing its ability to respond to customers of its popular XCub and other aircraft products by welcoming outside investors
• CubCrafters’ public investment offering was initially introduced last year through a Reg A+ filing qualified by the FTC in November, at which point more than $26 million of its $50 million goal had already been reserved pre-offering
• The company announced Jan. 17 that it has expanded that investment opportunity to residents in Florida, New Jersey, Texas, and Washington, through a Regulation CF campaign serving non-accredited investors who couldn’t qualify under the Reg A+ program
• Both investment offerings offer the same terms — $5 per share and a minimum investment of $400

The introduction of a new Regulation CF campaign by Yakima, Wash.-based aviation company CubCrafters has helped the best-in-class backcountry aircraft producer clear a critical hurdle to accepting investments from non-accredited investors in several states as a result of local restrictions in those states.

The allowance for investment from non-accredited investors living in Florida, New Jersey, Texas and Washington means it is now possible for investors in every state to participate in CubCrafters’ public offering if they wish.

“Our fans, customers, aviation enthusiasts, employees, and even the general public in the states of Florida, New Jersey, Texas, and Washington have told us that they very much want to participate in this investment opportunity,” CubCrafters President and CEO Patrick Horgan stated in the company’s news release (https://ibn.fm/lWwS4). “It was always our intention for everyone to be able to participate in our offering regardless of their location, and now they can.”

CubCrafters unveiled its plans to become a publicly funded company in July with an announcement that it would accept reservations for preferred stock under a Reg A+ filing, and in November Horgan announced the Federal Trade Commission (“FTC”) qualified the Reg A+ filing, opening the door for the investors to come onboard (https://ibn.fm/8OdXy).

The new Regulation CF campaign offers the same terms for preferred stock to the public — an initial price of $5 per share and a minimum investment of $400, according to the company.

The company aims to raise up to $50 million and had already received reservations for more than $26 million of its shares within 90 days of its announcement it would accept outside investment for the first time.

CubCrafters builds popular FAA-certified aircraft, light sport airplanes that meet international air traffic flow management (“ATFM”) standards, experimental aircraft for hands-on builders taking advantage of the company’s assistance program, and kits for those prepared to work on their own.

The purpose of the funding drive is to help the company grow sufficiently that it can reduce customers’ wait times (currently booked out at about two years) while also enabling the company to accelerate the pace of innovation to develop faster, more powerful, technically capable aircraft, to improve customer support, and to boost sales in overseas markets where the company flagship XCub aircraft has received international certifications.

Its XCub and Carbon Cub SS models are advanced versions of the legacy Super Cub using current-day technology — a high-performance fixed-wing craft useful for accessing backcountry areas without the need for paved runways, whether for commercial needs or for personal recreation.

The airplanes have lower operational costs than helicopters, which have also made them attractive to the government, leading to a contract with the U.S. Department of Agriculture announced last month to replace some of its aging Piper PA-18 Super Cubs currently in its fleet.

“Our goal here at CubCrafters is to provide them with such a good platform (an aircraft that is more capable, more cost effective, and safer), that they ultimately replace their entire current fleet of around 40 legacy aircraft with the XCub,” Vice President of Sales and Marketing Brad Damm told Flying magazine (https://ibn.fm/1l223).

For more information, visit the company’s website at www.CubCrafters.com.

NOTE TO INVESTORS: The latest news and updates relating to CubCrafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

• MetAlert recently announced the planned acquisition of TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications
• The acquisition is expected to add several products to MetAlert’s existing suite of products, one of which is an RFID and Bluetooth-enabled tracking technology called SafetyNet(R)
• The SafetyNet Tracking System comprises the SafetyNet Bracelets that patients wear, and a receiver-antenna combo used by police departments and first responders
• The Chelmsford Police Department in Massachusetts recently reported it had successfully located a missing senior citizen with dementia because of its participation in the SafetyNet program
• The department has, over time, established that radio frequency can be superior to GPS at successfully tracking missing persons, especially in challenging conditions such as densely wooded areas, buildings, basements, and shallow water

MetAlert (OTC: MLRT), a pioneer in smart, mobile, and wearable GPS tracking and recovery location-based products and services, is implementing a solid growth strategy that has seen it enter into a Heads of Terms agreement to acquire TrakTec LLC, a Florida-based leader in location awareness technology for consumer and business applications. Announced January 11, the agreement is expected to close on or before March 17 this year upon completing satisfactory due diligence and audits (https://ibn.fm/uzKUZ).

The acquisition is expected to add iGPS products, namely the Wizard GPS Tracking Watch Phone for children and the Phoenix GPS-based smartwatch for seniors, and SafetyNet(R), a radio-frequency identification (“RFID”) and Bluetooth-enabled tracking technology, to MetAlert’s existing suite of mostly GPS-based tracking products. Of the additions, SafetyNet stands out because of radio frequency’s unique advantages over GPS in certain outdoor environments.

TrakTec’s SafetyNet System comprises bracelets designed to be worn on the wrist or ankles at all times and individually emit a unique signal that represents the wearable’s own RFID. It is this RFID that is then fed into a receiver to enable tracking. The receivers are meant to be operated by law enforcement officials as part of the SafetyNet Tracking Systems program, with the police departments receiving handheld and vehicle-mounted antennas that isolate and boost the RF produced by the bracelets. Generally, the SafetyNet Tracking System is intended to help public safety agencies quickly locate patients with such conditions as autism, Alzheimer’s disease, and dementia.

Once an alert goes out that a SafetyNet user is missing, the first responders whose vehicle is equipped with an antennae head to the missing person’s last known location. This antenna, which isolates the incoming signals from the bracelet, allows the responders to track the location of the missing person up to a proximity of about a quarter of a mile, at which point the responders shift to the handheld tracking device that has a directional antenna. This device enables the responders to further isolate the person’s location and eventually find them.

Since its formation in 2010, SafetyNet has been deployed in more than 1,000 rescue cases (https://ibn.fm/9FU2W) and is utilized by police departments across more than 15 US states (https://ibn.fm/cN3Ws). One of these departments, the Chelmsford Police Department in Massachusetts, recently reported successfully locating a missing senior citizen with dementia because of its participation in the SafetyNet program (https://ibn.fm/N2aHK).

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation
• Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions
• Data collection from all study groups expected by April 2023
• SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. Research into psychedelics like psilocybin has recently experienced a renaissance, specifically for treating depression, addiction, anxiety, obsessive-compulsive disorder, and inflammatory diseases (https://ibn.fm/vnsO7). Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar disorder, and chronic pain. “The UCSF research team is making progress on the clinical trial,” said Eric Weisblum, Chief Executive Officer of Silo Pharma (https://ibn.fm/h7cAA). “The data gathered from these studies could uncover the role of inflammatory activity on such conditions as Parkinson’s, bipolar disorder, and chronic pain. Utilizing psilocybin in this study in a regimented dosing pattern, we hope to gain significant data both in mechanism of action and potential biomarker for personalization of psilocybin therapy.  The targeted patient populations from the study could provide support for the development and use of psilocybin as a therapeutic coupled with our novel homing peptides and topical technology.” The clinical study comprises preparation therapy, two separate dosing sessions with psilocybin, and integration therapy for the three patient populations afflicted with Parkinson’s disease, bipolar disorder, and chronic pain. Blood samples are collected from each patient at four points: one at baseline before treatment begins, one at 24 hours following both dosing sessions, and one after 30 days during a follow-up session. Data collection from the study is expected to be completed by April 2023 for all three patient populations. In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a joint partnership agreement with Columbia University (https://ibn.fm/9OQtD). The company initially entered a sponsored pact with the university in October 2021 and has recently extended the contract to continue research for SPC-14 and SPC-15, a targeted therapeutic for stress-induced anxiety disorders (https://ibn.fm/969lZ). Silo Pharma Inc. is fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological disorders. The company partners with leading institutions such as Columbia University, the University of California San Francisco (“UCSF”), and the University of Maryland, Baltimore (“UMB”) to develop treatments the company believes will transform healthcare and improve patient outcomes. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• The February 15, 2023 Investor Day virtual event will be hosted by the company’s President and CEO, Brian Haugli, and CFO, Ryan Polk
• Reports have shown an increase in cyberattacks due to the growth in network attack surfaces for in-office and remote workers who rely on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business
• SideChannel’s newest product release, Enclave(TM), is a comprehensive cloud and network solution that enables IT teams to contain breaches faster, reduce network outages, minimize latency, and strengthen overall defensive security

SideChannel (OTCQB: SDCH), a provider of cybersecurity services and technology, develops technologies to make cybersecurity simple and accessible, by matching organizations worldwide with expert virtual Chief Information Security Officers (vCISOs), allowing companies to assess cyber risk and ensure cybersecurity compliance, without jeopardizing financial assets. The company has announced its Investor Day event to be held virtually on February 15, 2023, from 9:00 am to 10:30 am EST (https://ibn.fm/LG5ZY). Investor Day will be hosted by SideChannel’s President and CEO, Brian Haugli, and CFO, Ryan Polk, who will provide updates on the Company’s operations, recent developments, and strategic priorities. SideChannel will accept questions from investors via email before the event, which can be submitted to ir@sidechannel.com. Investors planning to attend SideChannel’s Investor Day event will need to preregister for the event by filling out an online form (https://ibn.fm/YvCR1). SideChannel is committed to creating top-tier cybersecurity programs for small and mid-sized businesses, helping them protect their data and assets, and has created over 50 multi-layered cybersecurity programs for clients. The company lends its talents to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for growing enterprises. Reports have shown that cyberattacks on these types of businesses have increased in recent years due to the exponential growth of network attack surfaces. More remote and in-office workers rely on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business. With this in mind, SideChannel is continually expanding its service offerings, workforce, and customer base – attracting over 20 vCISOs to serve across a vast number of industries, including fintech, biotech, healthcare, manufacturing, legal, defense, and technology services. SideChannel’s recent product offering includes Enclave(TM), a comprehensive cloud and network solution that enables IT teams to contain breaches faster, reduce network outages, minimize latency, and strengthen overall security defense. Enclave creates the foundation for a zero-trust network security model that IT can build upon, segmenting a company’s network to organize personnel and computing devices at the employee level and implement security controls across all network segments. The cybersecurity market is projected to reach $173.5 billion by the end of 2023, with security services anticipated to be the largest segment valued at $91.21 billion. The average spend per employee in the cybersecurity market is projected to reach $8,190 in 2023. The market is expected to grow at a CAGR of 10.9%, resulting in a revenue volume of $262.4 billion by 2027. Compared to global revenue, the United States is expected to account for approximately $69.7 million in 2023 (https://ibn.fm/nsWa0). Enclave was designed and purpose-built to serve the growing security needs of small to mid-sized organizations. This traditionally underserved market is more prone to cyber-attacks but has limited protection due to smaller budgets, inadequate IT security staffing, and a lack of cybersecurity awareness among top executives. SideChannel’s product is affordable and effective – shrinking the attack surface area exposed to cyber intruders and significantly reducing the effort required to operate securely. For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH